IRIS
ALFIERI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.800
AS - Asia 9.401
EU - Europa 7.255
SA - Sud America 1.263
AF - Africa 493
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 5
Totale 29.230
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.564
SG - Singapore 3.290
CN - Cina 2.702
VN - Vietnam 1.580
IT - Italia 1.458
IE - Irlanda 1.110
FI - Finlandia 1.074
BR - Brasile 1.007
SE - Svezia 940
DE - Germania 751
HK - Hong Kong 668
UA - Ucraina 488
FR - Francia 363
ZA - Sudafrica 311
NL - Olanda 296
TR - Turchia 291
IN - India 208
GB - Regno Unito 192
RU - Federazione Russa 168
CA - Canada 142
AR - Argentina 104
AT - Austria 97
BD - Bangladesh 90
BE - Belgio 85
CI - Costa d'Avorio 74
JP - Giappone 67
IQ - Iraq 63
MX - Messico 58
ID - Indonesia 54
PL - Polonia 54
KR - Corea 53
PK - Pakistan 43
PH - Filippine 41
ES - Italia 40
EC - Ecuador 38
CO - Colombia 36
CZ - Repubblica Ceca 33
TH - Thailandia 30
UZ - Uzbekistan 28
MA - Marocco 27
LT - Lituania 25
VE - Venezuela 23
SA - Arabia Saudita 21
IR - Iran 18
JO - Giordania 17
EG - Egitto 16
KE - Kenya 16
TN - Tunisia 15
PY - Paraguay 14
MY - Malesia 13
TW - Taiwan 13
AL - Albania 12
AZ - Azerbaigian 11
CL - Cile 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
RO - Romania 10
AU - Australia 9
BO - Bolivia 9
DZ - Algeria 9
HU - Ungheria 9
KZ - Kazakistan 9
LB - Libano 9
NP - Nepal 9
PE - Perù 9
PS - Palestinian Territory 9
GE - Georgia 7
JM - Giamaica 7
LU - Lussemburgo 7
OM - Oman 7
SY - Repubblica araba siriana 7
EE - Estonia 6
IL - Israele 6
KG - Kirghizistan 6
MD - Moldavia 6
CH - Svizzera 5
CR - Costa Rica 5
ET - Etiopia 5
PA - Panama 5
DO - Repubblica Dominicana 4
GT - Guatemala 4
HN - Honduras 4
NZ - Nuova Zelanda 4
QA - Qatar 4
AM - Armenia 3
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
BW - Botswana 3
DK - Danimarca 3
HR - Croazia 3
LV - Lettonia 3
SI - Slovenia 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
CY - Cipro 2
EU - Europa 2
GA - Gabon 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 29.197
Salva come PNG Salva come JPEG
Città #
Singapore 1.683
Ashburn 1.184
Dublin 1.107
Chandler 1.038
Dallas 943
San Jose 862
Beijing 638
Santa Clara 634
Hong Kong 621
Jacksonville 560
Ann Arbor 508
Parma 492
Ho Chi Minh City 482
Dearborn 397
Boardman 346
Hanoi 340
Johannesburg 299
Nanjing 255
Los Angeles 235
New York 235
Izmir 234
Shanghai 230
Munich 198
Lauterbourg 196
Princeton 196
San Mateo 169
Hefei 141
Bremen 135
Wilmington 115
Helsinki 108
Milan 107
Chicago 101
São Paulo 98
Nanchang 92
Kunming 88
Moscow 83
Shenyang 82
Haiphong 80
Vienna 80
Jinan 76
Toronto 76
Buffalo 75
Abidjan 74
Hebei 74
Council Bluffs 71
Woodbridge 68
Brussels 67
Des Moines 67
Da Nang 59
Marseille 57
Frankfurt am Main 56
Tianjin 56
The Dalles 49
Columbus 47
Pune 47
Seattle 47
Bologna 46
Turku 46
Guangzhou 44
Tokyo 43
Houston 42
Jiaxing 42
Amsterdam 41
Warsaw 41
Changsha 40
Modena 39
London 38
Brooklyn 37
Stockholm 35
Jakarta 34
Rio de Janeiro 34
Denver 33
Düsseldorf 30
Seoul 29
Biên Hòa 27
Hangzhou 27
Phoenix 27
Tashkent 27
Norwalk 26
Dhaka 24
Manchester 24
Orem 24
Reggio Emilia 24
Rome 24
Atlanta 23
Belo Horizonte 23
Brasília 23
Hải Dương 23
Montreal 23
Redmond 23
Chennai 22
Leawood 22
Nuremberg 22
San Francisco 22
Campinas 21
Baghdad 20
Curitiba 20
Fremont 20
Zhengzhou 20
Poplar 19
Totale 17.752
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 273
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 242
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 210
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 209
Allotrapianto di polmone sinistro nel coniglio.Modello sperimentale per lo studio della conservazione del polmone. 206
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 205
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 204
Cell size reduction induced by inhibition of the mTOR/S6K signaling pathway protects Jurkat cells from apoptosis 202
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 191
Characterization of gefitinib uptake in NSCLC cell lines 189
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 188
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 185
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 181
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 180
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 179
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 179
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 178
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 177
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 176
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 176
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 176
5-benzylidene-hydantoins as new inhibitors of cell proliferation 176
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 175
Antitumoral effect of a nanotechnology-based photodynamic therapy. 175
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 169
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 166
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Attenuated expression of 70kDa heat shock protein in WI-38 human fibroblasts during aging in vitro 164
An original application of plasma expanders: heart-lung preservation. 164
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 160
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 160
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 160
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 159
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Attenuata induzione del gene SNAT-2 in fibroblasti umani senescenti esposti a stress iperosmolare 156
Methodology for the assessment of lung protection. Human pulmonary artery endothelial cell preservation using haemaccel. 156
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 156
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
155P Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models 154
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 154
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 153
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 150
An effective solution for prolonged preservation of cultured human pulmonary artery endothelial cells 149
Drug-induced cellular death dynamics monitored by a highly sensitive organic electrochemical system 148
) Sperimentazione su pneumociti di tipo II per la conservazione del polmone in funzione del trapianto. Soluzioni idroelettrolitiche a confronto. 147
SiO2/SiC core-shell nanowires for nanomedicine applications 147
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 146
New MDR1 inhibitors for overcoming multidrug resistance 146
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Anti-proliferative and pro-apoptotic effects of soarfenib in MCF-7/AROM-1 breast cancer cells. 144
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 144
A new extracellular type solution for lung preservation: "in vitro" comparison with Beltzer, low potassium Dextran and Euro-Collins solutions by means of human lung fibroblasts. 144
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 144
Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC 144
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives 144
5'-Untranslated region of heat shock protein 70 mRNA drives translation under hypertonic conditions 144
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 144
Clinical perspective for irreversible tyrosine kinase inhibitors in cancer 144
Alterazioni della degradazione proteasoma-dipendente nel corso dell'invecchiamento ed effetti delle restrizioni caloriche 143
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
SiO2/SiC core-shell nanowires for nanomedicine applications 141
Activation of heat-shock transcription factor 1 by hypertonic shock in 3T3 cells 140
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 140
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 139
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 139
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 139
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 136
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
Totale 17.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 95.551
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021397 0 0 0 0 0 0 0 0 0 49 287 61
2021/20221.011 44 22 52 65 34 14 135 119 60 71 67 328
2022/20234.206 399 434 276 278 414 466 44 297 1.364 25 169 40
2023/20241.762 86 139 60 64 157 403 129 131 68 88 155 282
2024/20255.391 177 281 345 406 496 566 305 223 737 463 472 920
2025/202610.823 1.026 1.078 1.418 1.061 1.562 659 1.286 362 1.625 746 0 0
Totale 29.562